The FDA has issued a complete response letter (CRL) to a new drug application (NDA) for Dasynoc for the treatment of chronic ...

Real world evidence on treatment efficacy and safety of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.

IMproveMF update: Phase 1/1B trial of imetelstat (IME)+ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1, INT-2, or high-risk (HR) myelofibrosis (MF). This is an ASCO Meeting Abstract from ...

Asciminib, a first-in-class BCR-ABL1 TKI, showed high molecular response rates and was well tolerated in the first prospective trial of its kind evaluating the drug as a dose-escalated second-line ...

June 14, 2006 — Two new drugs overcome the resistance that can develop to the first-line-therapy imatinib ( Gleevec, Novartis) in chronic myeloid leukemia (CML), and results from phase 1 clinical ...

Thanks to efforts from doctors, researchers, health care providers and nonprofits such as Blood Cancer United, certain types of blood cancers are not the terminal diagnoses that these were decades ago ...

Chronic Myeloid Leukemia is a type of blood cancer that once used to be considered fatal disease, but with a clinical trial conducted in Australia in 2001, came Imatinib drug, also called magic bullet ...